Bayer/Regeneron's Eylea heading for early DME market entry
This article was originally published in Scrip
Regeneron and Bayer's eye product Eylea (aflibercept) has notched up Phase III success in a fourth indication, diabetic macular edema (DME). Both companies expect to file for expanded approval of the drug in this indication this year – Regeneron in the US and Bayer in the EU. The US filing will come about a year ahead of schedule, Regeneron noted.
You may also be interested in...
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent
Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.